WuXi AppTec在Q3上的利润较高,并由于生物药品需求强劲和积压现象不断增加,提高了全年收入前景。 WuXi AppTec posted higher Q3 profits and raised its full-year revenue outlook due to strong biopharma demand and growing backlog.

WuXi AppTec报告,第三季度利润大幅上升,净收入从上一年的22.93亿元增至35.15亿元,调整后的非国际财务报告准则净利润从29.74亿元增至42.2亿元。 WuXi AppTec reported a significant rise in third-quarter profits, with net income reaching RMB 3.515 billion, up from RMB 2.293 billion the previous year, and adjusted non-IFRS net profit at RMB 4.22 billion, up from RMB 2.974 billion. 季度收入从10 461亿元增加到120.570亿元。 Quarterly revenue increased to RMB 12.057 billion from RMB 10.461 billion. 该公司将其全年收入预测提高到435亿至440亿林吉特,理由是对其生物制药服务的需求强劲,而且持续经营的积压年增长率为41.2%。 The company raised its full-year revenue forecast to RMB 43.5 billion–RMB 44.0 billion, citing strong demand for its biopharmaceutical services and a 41.2% year-over-year increase in backlog for continuing operations. 它还表示有信心在2025年改善其调整后的非国际财务报告准则净利润率。 It also expressed confidence in improving its adjusted non-IFRS net profit margin in 2025.